TWD 30.0
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 472.87 Million TWD | -6.83% |
2022 | 507.53 Million TWD | -16.65% |
2021 | 608.89 Million TWD | -1.34% |
2020 | 617.14 Million TWD | 0.0% |
2019 | - TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 622.6 Million TWD | 31.66% |
2024 Q2 | 625.3 Million TWD | 0.43% |
2023 Q3 | 816.8 Million TWD | 62.3% |
2023 Q2 | 503.26 Million TWD | -1.94% |
2023 FY | 472.87 Million TWD | -6.83% |
2023 Q1 | 513.22 Million TWD | 0.0% |
2023 Q4 | 472.87 Million TWD | -42.11% |
2022 Q4 | - TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | 48.042% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | -67.367% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | 19.85% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 85.963% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 86.965% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 92.888% |
Center Laboratories, Inc. | 6.78 Billion TWD | 93.032% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | -193.616% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | 46.998% |
InnoPharmax Inc. | 48.64 Million TWD | -872.012% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | -47.316% |
DV Biomed Co., Ltd. | 765.87 Million TWD | 38.257% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | 23.351% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | -68.354% |
UniPharma Co., Ltd. | 37.4 Million TWD | -1164.335% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 53.427% |
Alar Pharmaceuticals Inc. | 76.08 Million TWD | -521.475% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | -26.479% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -851.055% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | -334.819% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | -253.879% |